Shattuck Labs(STTK) - 2023 Q3 - Earnings Call Transcript

Conor Richardson Thanks, Taylor, and good morning, everyone. 2023 continues to be a year of focused operational execution. IÂ'm grateful for the relentless efforts of our team, our participating investigators and most importantly, the patients themselves that have enabled this progress. For clinical program milestones, we expect to complete enrollment in the frontline higher-risk MDS cohort in the fourth quarter of 2023. We also plan to complete enrollment of our Phase 1B dose expansion cohort of SL172154 i ...